Resolving inflammation
at its core
Citryll is pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs), a fundamental driver of inflammation that has yet to be addressed therapeutically. Citryll is developing the first ET-targeting therapy, with the potential to establish a new therapeutic class for immune-mediated inflammatory diseases.
Our latest webinar:
The emerging role of extracellular traps in immune-mediated inflammatory diseases
Targeting an unaddressed biology for treatment of immune mediated inflammatory disorders
Citryll is targeting ETs as a fundamental driver of inflammation in many immune mediated inflammatory diseases, with a focus on rheumatoid arthritis (RA) and hidradenitis suppurativa (HS) as therapeutic development areas for CIT-013. Our lead asset, CIT-013, is a first-in-class monoclonal antibody with a unique dual mechanism of action. CIT-013 has demonstrated a powerful ability to inhibit ET formation and enhance ET clearance, addressing a key component of inflammation. By intervening in this process, CIT-013 aims to overcome the limitations of therapies that target individual cytokines or downstream pathways.
Latest news
New research published in Frontiers in Immunology highlights CIT-013’s ability to modulate macrophage responses and promote inflammation resolution
Citryll has published new preclinical research that deepens the understanding of how CIT-013, the Company’s first-in-class monoclonal antibody, modulates immune...
Exploring the Emerging Role of Extracellular Traps in Immune-Mediated Inflammatory Diseases
Earlier this week, Citryll hosted an educational webinar bringing together leading scientific and clinical experts to discuss the evolving understanding...
Latest publications
Antibody-opsonized extracellular traps modulate macrophage responses and attenuate their T cell-associated inflammatory and costimulatory characteristics
Immunothrombosis Promotes The Interaction Between Neutrophils And Synovial Fibroblasts In Rheumatoid Arthritis
Conference calendar
Clinical trial opportunities for patients
Citryll is conducting clinical trials for CIT-013, an investigational therapy developed to address Rheumatoid Arthritis (RA) and Hidradenitis Suppurativa (HS). This clinical research seeks to understand CIT-013’s potential effectiveness, safety, and impact on patient quality of life. We expect two clinical trials to start by mid 2025.